Expression of activated signal transducer and activator of transcription-3 predicts poor prognosis in cervical squamous-cell carcinoma

S Takemoto*,1, K Ushijima1, K Kawano1, T Yamaguchi2, A Terada1, N Fujiyoshi1, S Nishio1, N Tsuda1, M Ijichi1, T Kakuma1, M Kage2, D Hori1 and T Kamura1

1Department of Obstetrics and Gynecology, Kurume University School of Medicine, Fukuoka, Japan; 2Department of Pathology, Kurume University School of Medicine, Fukuoka, Japan; 3Biostatistics Center, Kurume University School of Medicine, Fukuoka, Japan

BACKGROUND: Stat3 is a member of the Janus-activated kinase/STAT signalling pathway. It normally resides in the cytoplasm and can be activated through phosphorylation. Activated Stat3 (p-Stat3) translocates to the nucleus to activate the transcription of several molecules involved in cell survival and proliferation. The constitutive activation of Stat3 has been shown in various types of malignancies, and its expression has been reported to indicate a poor prognosis. However, the correlation between the constitutive activation of Stat3 and the prognosis of cervical cancer patients has not been reported.

METHODS: The immunohistochemical analysis of p-Stat3 expression was performed on tissues from 125 cervical squamous-cell carcinoma patients who underwent extended hysterectomy and pelvic lymphadenectomy, and the association of p-Stat3 expression with several clinicopathological factors and survival was investigated.

RESULTS: Positive p-Stat3 expression was observed in 71 of 125 (56.8%) cases and was significantly correlated with lymph node metastasis, lymph vascular space invasion, and large tumour diameter (>4 cm) by Fisher’s exact test. Kaplan–Meier survival analysis showed that p-Stat3 expression was statistically indicative of a poor prognosis for overall survival (P = 0.006) and disease-free survival (P = 0.010) by log-rank test.

CONCLUSION: These data showed that p-Stat3 expression in cervical cancer acts as a predictor of poor prognosis.

British Journal of Cancer (2009) 101, 967–972. doi:10.1038/sj.bjc.6605212 www.bjcancer.com

MATERIALS AND METHODS

Human tissue specimens and patient information

Tumour tissue was collected from 125 cervical cancer patients with invasive squamous-cell carcinoma who had undergone extended hysterectomy and pelvic lymphadenectomy. The expression of p-Stat3 and its association with several clinicopathological factors and survival were investigated in this study. The association of p-Stat3 expression with lymph node metastasis, lymph vascular space invasion, and large tumour diameter (>4 cm) by Fisher’s exact test and Kaplan–Meier survival analysis showed that p-Stat3 expression was statistically indicative of a poor prognosis for overall survival (P = 0.006) and disease-free survival (P = 0.010) by log-rank test.

Keywords: cervical cancer; signal transducer and activator of transcription-3; immunohistochemical study; squamous-cell carcinoma
hysterectomy with pelvic lymphadectomy at Kurume University Hospital between 1996 and 2005. Normal cervical tissue was also collected from five removed uteri without malignancy, which served as a control. We studied the follow-up information through May 2007 from patient medical records, with a median follow-up period of 50 months. Histopathological diagnosis was based on World Health Organization classifications, and clinical staging was made according to the International Federation of Gynecology and Obstetrics system. Postoperatively, adjuvant treatment was given in the case of lymph node metastasis, lymph vascular space invasion (LVSI), large tumour diameter (>4 cm), deep stromal invasion (>4/5), invasion into the parametrium, and positive status for surgical margin. The use of tissue blocks and chart review was approved by the Institutional Review Board of Kurume University Hospital.

Immunohistochemical analysis

Sections (3 μm thick) of formalin-fixed, paraffin-embedded tumour specimens were deparaffinised in xylene and rehydrated in graded alcohol. Antigen retrieval was carried out in Tris/EDTA buffer (Dako Target Retrieval Solution, pH 9.0, DAKO, Kyoto, Japan) by heating in a microwave oven for 30 min at 99°C. The specimens were incubated at 4°C overnight in a 1:25 dilution of goat affinity-purified polyclonal antibody against p-Stat3 (Tyr-705, sc-7993, Santa Cruz Biotechnology, Santa Cruz, CA, USA). Slides were washed three times in phosphate-buffer solution and further incubated with a biotinylated secondary antibody for 30 min at room temperature. Next, the slides were rinsed with phosphate-buffer solution and incubated for 5 min with diaminobenzidine. The sections were washed twice with distilled water, counterstained with haematoxylin for 1 min, and washed once each with distilled water and phosphate-buffer solution. Afterwards, the slides were mounted and examined using a bright-field microscope. Two investigators independently evaluated and interpreted the results of immunostaining without knowledge of the clinical data for each patient. In our condition, the positive rate of nuclear staining was less than 10% in most cases and a significant difference was not observed with regard to the intensity of staining. Therefore, the existence of nuclear staining was considered positive immunoeexpression. We further categorised the positive group into two subgroups for a detailed analysis of lymph node metastatic patients. Local staining up to 5% of the tumour area was defined as +, and staining over 5% of the area was defined as ++, respectively.

Transfection of Stat3 small interfering RNA

Pre-designed siRNA (small interfering RNA) Reagent ON-TARGET plus against STAT3 and siSTABLE Non-Targeting siRNA no. 1 were purchased from Dharmaco (Lafayette, CO, USA). Two sets of siRNA were transacted into the cervical cancer cell line, SKG II cells, with lipofectAMINE 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocol. Cells were allowed to proliferate in wells for 48 h.

Western blotting

Cells were collected and lysed by LDS sample buffer (Invitrogen). Protein concentrations were quantitated using the DC protein assay kit (Bio-Rad, Hercules, CA, USA) according to the manufacturer’s protocol. Equal amounts of cellular proteins were electrophoretically fractionated in 10% PAGE gels, transferred to nitrocellulose membranes, and subjected to immunoblot analysis with specific antibodies against p-Stat3 (Cell Signaling Technology, Beverly, MA, USA) and Bcl-xl, vascular endothelial growth factor (VEGF) (Santa Cruz Biotechnology), and β-actin (Sigma-Aldrich, St Louis, MO, USA). Specific bands were visualised using the chemiluminescence reagent kit (Amersham ECL and ECL advance Western Blotting Analysis System; GE Healthcare, Chalfont St Giles, UK). Specific bands were quantified by scanning densitometry using the Image J1.34 software (NIH, Bethesda, MD, USA) version 1.61. The expression status of each sample was standardised by the expression status of β-actin.

Statistical analysis

Statistical analysis was performed using the SAS statistical package version 9.1.3 (SAS Institute Inc., Cary, NC, USA). Survival curves were generated using the Kaplan–Meier method, and comparisons between survival curves were made using a log-rank test. Fisher’s exact test was used to analyse discrete variables, and the Jonckheere–Terpstra test was used to analyse the association between the number of lymph nodes and the intensity of p-Stat3 immunoeexpression. Multivariate survival analysis was conducted using the Cox proportional hazard method. Only P-values less than 0.05 were considered statistically significant.

RESULTS

Patient characteristics

The 5-year overall and disease-free survival rates of all patients were 86.1 and 83.1%, respectively. Patient characteristics were presented in Table 1. Significantly low 5-year overall survival rates were seen in patients with the factors of FIGO stage II, large tumour diameter (>4 cm), deep stromal invasion (>4/5), LVSI, parametrial invasion, and lymph node metastasis (log-rank test, data not shown). Significantly low rates of 5-year disease-free survival were shown in patients with factors such as large tumour diameter (>4 cm), deep stromal invasion (>4/5), LVSI, parametrial invasion, and lymph node metastasis (log-rank test, data not shown).

Expression of p-Stat3 in cervical cancer tissue and normal cervical tissue

Phosphorylated-Stat3 was expressed only in the nuclei of the tumour cells (Figure 1A) and was not expressed in the nuclei or cytoplasm of normal cells (Figure 1B). Nuclear staining of p-Stat3 was observed in less than 10% of cells in most cases. It was impossible to evaluate the intensity of p-Stat3 staining because no significant difference of intensity status was observed. Therefore, we defined all cases that show nuclear staining of p-Stat3 as positive. No normal cervical tissues were stained with p-Stat3.

Correlation between clinicopathologic factors and p-Stat3 expression

The correlation between clinicopathological features and positive expression of p-Stat3 is summarised in Table 2. Positive expression of p-Stat3 was significantly associated with large tumour diameter (> 4 cm), LVSI, and lymph node metastasis.

Correlation between lymph node metastases and p-Stat3 expression

Of the 32 patients with lymph node metastasis, 14 had one node, 7 had two nodes, and 11 had three or more nodes with metastasis. The percentage of p-Stat3 expression status in each group is shown in Figure 2. The relationship between p-Stat3 expression and these three groups was significant, accounting for ordered categories on both factors (P = 0.022; Jonckheere–Terpstra test).
Prognostic significance of p-Stat3 expression

During the follow-up on 125 patients (with a median follow-up of 50 months), 18 patients (14.4%) developed recurrence and 16 patients (12.8%) died of disease. Among the 125 tumours, 54 tumours (43.2%) were negative and 71 (56.8%) were positive for p-Stat3 expression. The overall and disease-free survival rates were determined using the Kaplan–Meier method. The 5-year overall survival rate for patients with positive expression of p-Stat3 and negative expression of p-Stat3 was 79.2 and 95.3%, respectively. The overall survival rate was significantly higher in patients with p-Stat3-negative tumours than in those with p-Stat3-positive tumours ($P = 0.006$; log-rank test; Figure 3A). Similarly, the 5-year disease-free survival rate for patients with positive p-Stat3 expression and negative p-Stat3 expression was 76.8 and 92.3%, respectively, and the disease-free survival rate in patients with negative tumours was significantly higher than that in patients with positive tumours ($P = 0.010$; log-rank test; Figure 3B). However, positive p-Stat3 expression was not an independent prognostic factor in multivariate analysis for overall and disease-free survival (data not shown).

Eighteen of the 125 patients in our study developed recurrence during the follow-up period. Of these, 12 had recurrence at a distant site and 6 had local recurrence. Positive expression of p-Stat3 was found in 10 (83.3%) tumours of distant recurrence and 5 (83.3%) tumours of local recurrence. There was no correlation between p-Stat3 expression and the pattern of recurrence.

Table 1 Clinical and pathological characteristics

| Characteristics                  | Number (%) |
|----------------------------------|------------|
| Age, Median                      | 47 (19–77) |
| <47                              | 62 (49.6)  |
| ≥47                              | 63 (50.4)  |
| FIGO stage                       |            |
| I                                | 90 (72.0)  |
| Ib1                              | 11 (8.8)   |
| Ib2                              | 11 (8.8)   |
| III                              | 13 (10.4)  |
| Tumour size                      |            |
| ≤4 cm                            | 109 (87.2) |
| >4 cm                            | 16 (12.8)  |
| Stromal invasion                 |            |
| ≤4/5                             | 86 (68.8)  |
| >4/5                             | 39 (31.2)  |
| LVI                              |            |
| Absent                           | 60 (48.0)  |
| Present                          | 65 (52.0)  |
| Parametrium invasion             |            |
| Absent                           | 115 (92.0) |
| Present                          | 10 (8.0)   |
| No. of metastatic LN             |            |
| None                             | 93 (74.4)  |
| 1                                | 14 (11.2)  |
| 2                                | 7 (5.6)    |
| ≥3                               | 11 (8.8)   |
| Adjuvant therapy                 |            |
| None                             | 62 (49.6)  |
| RT                               | 40 (32.0)  |
| CCRT                             | 9 (7.2)    |
| CT                               | 2 (1.6)    |
| CT+RT                            | 12 (9.6)   |

CCRT = concurrent chemoradiation; CT = chemotherapy; LN = lymph nodes; LVI = lymph vascular space invasion; RT = radiotherapy.

Table 2 Correlation between clinicopathologic variables and p-Stat3 expression using Fisher’s exact test

| Variable                  | n   | p-Stat3 positive (%) | P-value |
|---------------------------|-----|----------------------|---------|
| FIGO stage                |     |                      |         |
| I                         | 101 | 53 (52.5)            | 0.006   |
| II                        | 24  | 18 (66.7)            |         |
| Tumour size               |     |                      |         |
| ≤4 cm                     | 109 | 56 (51.4)            | 0.001   |
| >4 cm                     | 16  | 15 (93.8)            |         |
| Stromal invasion          |     |                      |         |
| ≤4/5                      | 86  | 45 (52.2)            | 0.173   |
| >4/5                      | 39  | 26 (66.7)            |         |
| LVI                       |     |                      |         |
| Absent                    | 60  | 26 (43.3)            | 0.004   |
| Present                   | 65  | 45 (69.2)            |         |
| Parametrium invasion      |     |                      |         |
| Absent                    | 115 | 63 (54.8)            | 0.185   |
| Present                   | 10  | 8 (80.0)             |         |
| LN metastasis             |     |                      |         |
| Absent                    | 93  | 46 (49.5)            | 0.007   |
| Present                   | 32  | 25 (78.1)            |         |

LN = lymph nodes; LVI = lymph vascular space invasion.

Figure 1 Immunoexpression of p-Stat3 in cervical cancer specimen (A), and normal cervical tissue (B). Only tumour cell nuclei were stained.
Expression of Bcl-xL and VEGF was reduced by inhibiting the expression of Stat3

Expression of p-Stat3 in all five cervical cancer cell lines was confirmed by western blotting analysis (data not shown). Transfection of siRNA against Stat3 into cervical cancer cell line, SKG II, induced the inhibition of expression of pStat3. Furthermore, the expression of Bcl-xL and VEGF, which are reported to be downstream molecules of Stat3, was decreased (Figure 4).

DISCUSSION

In this study, we found that Stat3 was activated in 56.8% of cervical squamous-cell carcinomas in immunohistochemical analysis and the expression of activated Stat3 (p-Stat3) significantly correlated with a worse prognosis in patients with this disease by univariate analysis. Immunoexpression of p-Stat3 has been recognised as a predictor of poor survival in other malignancies (Horiguchi et al, 2002; Masuda et al, 2002; Rosen et al, 2006; Yang et al, 2007), but, to our knowledge, the correlation between the p-Stat3 expression and prognosis in patients with cervical cancer has not been reported. It has been shown that p-Stat3 immunoexpression was significantly associated with lymph node metastasis or tumour size in other malignancies (Masuda et al, 2002; Kusaba et al, 2005; Suiqing et al, 2005; Shah et al, 2006). Some clinicopathological parameters such as FIGO stage, tumour size, deep stromal invasion, LVI, parametrium invasion, lymph node metastasis, and the number of metastatic lymph nodes have been reported as predictors of poor prognosis in cervical cancer (Sakuragi et al, 1999; Waggoner, 2003; Kim et al, 2005). Therefore, we examined the possible correlation between such parameters and p-Stat3 expression in cervical cancer specimens, and found that p-Stat3 expression significantly correlated with lymph node metastasis, LVI, and large tumour size (>4 cm) in these patients. These factors might contribute to a worse prognosis in patients with Stat3 activation. On the other hand, no independent prognostic factor for overall survival was identified by multivariate analysis. Deep
stomal invasion (> 4/5) was the only independent prognostic factor for disease-free survival. Although p-Stat3 expression was not an independent prognostic factor for either overall survival or progression-free survival, probably because of the correlation with other clinicopathological factors in our study, it was interesting to observe that the hazard ratio was the highest in the significant prognostic factor by univariate analysis (data not shown). This result indicated that p-Stat3 expression can be an important factor to predict prognosis.

Only one immunohistochemical study has been reported on p-Stat3 expression in cervical cancer (Chen et al., 2007), in which the researchers reported that 25 specimens (24.0%) showed positive immunoeexpression of p-Stat3 in 104 cervical cancer specimens. This was a low occurrence rate compared with our result. This difference might be attributed to the histologic subtype or to the definition of positive expression; their data included other histological subtypes such as adenocarcinoma and micro-invasive carcinoma. They also defined weak-staining specimens as having a negative expression. Their report showed that p-Stat3 expression did not significantly correlate with any clinicopathological factors such as patient’s age, tumour grade, disease stage, lymph node metastasis, or histological type. However, information on clinicopathological factors seemed insufficient to draw any conclusions; approximately half the data on tumour grade, disease stage, and lymph node metastasis were not identified, and the researchers did not mention the prognostic of patients with p-Stat3 immunoeexpression. Although our result indicated that the activation of Stat3 contributed to a poor prognosis, the mechanism of constitutive activation of Stat3 has not been clarified well in cervical cancer. It is reported that the autocrine and/or paracrine system by IL-6, stimulation of EGF or Src (Zhong et al., 1994; Yu et al., 1995), mutation or overexpression of Stat3 (Bromberg, 2002; Huang et al., 2005) results in constitutive activation of Stat3 in other malignancies. Although a similar mechanism is considered in cervical cancer, there is no report other than that of Wei et al. (2003) that revealed the activation of Stat3 mediated by IL-6.

Furthermore, Wei et al. (2003) showed that the IL-6-mediated VEGF expression had been suppressed by Stat3 inhibition with a Stat3 dominant-negative mutant (DNStat3). In other malignancies, it has been suggested that the Stat3 signalling pathway regulates tumour progression by regulating downstream genes crucial to angiogenesis, proliferation, invasion, and immune evasion (Huang, 2007). Chen et al. (2007) showed that apoptosis had been induced by the inhibition of Stat3 with DNStat3 or JSI-124, a small molecular inhibitor of the Janus-activated kinase/STAT pathway in cervical cancer. Furthermore, they showed a significant correlation of expression between p-Stat3 and antiapoptotic molecules such as Bcl-XL, Mcl-1, and Survivin in immunohistochemical analysis. We also showed that the inhibition of p-Stat3 expression resulted in a downregulation of Bcl-XL and VEGF by western blotting analysis.

Recently, several inhibitors against Stat3 activation have been established that showed the induction of apoptosis or cell-cycle arrest in cancer cells, or decreased tumour volumes in vivo (Turkson et al., 2005; Xi et al., 2005; Duan et al., 2006; Hussain et al., 2007). Stat3 targeted therapy seems to be a promising new strategy for the treatment of cervical cancer.

In conclusion, p-Stat3 immunoeexpression was found to be a potent prognostic factor of cervical cancer. Stat3 might be a target of molecular therapy in cervical cancer.

ACKNOWLEDGEMENTS

This work was supported in part by the Fukuoka Obstetrics and Gynecology Researcher’s Charity Foundation Fund of Japan.

REFERENCES

Bromberg J (2002) Stat proteins and oncogenesis. J Clin Invest 109: 1139–1142
Campbell CL, Jiang Z, Savarese DM, Savarese TM (2001) Increased expression of the interleukin-1 receptor and evidence of STAT3 activation in prostate carcinoma. Am J Pathol 158: 25–32
Chen CL, Hsieh FC, Lieblein JC, Brown J, Chan C, Wallace JA, Cheng G, Hall BM, Lin J (2007) Stat3 activation in human endometrial and cervical cancers. Br J Cancer 96: 591–599
Duan Z, Bradner JE, Greenberg E, Levine R, Foster R, Mahoney J, Seiden MV (2006) SD-1029 inhibits signal transducer and activator of transcription 3 nuclear translocation. Clin Cancer Res 12: 6844–6852
Gouilleux-Gruant V, Gouilleux F, Desaingt C, Claïse JF, Capiod JC, Delobel J, Weber-Nordt R, Dusanter-Fourt I, Dreyfus F, Groner B, Prin L (1996) Stat-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. Blood 87: 1692–1697
Horiguchi A, Oya M, Shimada T, Uchida A, Marumo K, Murai M (2002) Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome. J Urol 168: 762–765
Huang HF, Murphy TP, Shu P, Barton AB, Barton BE (2005) Stable expression of constitutively-activated STAT3 in benign prostatic epithelial cells changes their phenotype to that resembling malignant cells. Mol Cancer 4: 2
Huang M, Page C, Reynolds RK, Lin J (2000) Constitutive activation of STAT3 oncogene product in human ovarian carcinoma cells. Gynecol Oncol 79: 67–73
Huang S (2007) Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway: clinical implications. Clin Cancer Res 13: 1362–1366
Hussain SF, Kong LY, Jordan J, Conrad C, Madden T, Fokt I, Priewe W, Heimberger AB (2007) A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res 67: 9630–9636
Kim JH, Kim HJ, Hong S, Wu HG, Ha SW (2005) Post-hysterectomy radiotherapy in FIGO stage IB-IB uterine cervical carcinoma. Gynecol Oncol 96: 407–414
Kusabu T, Nakayama T, Yamazumi K, Yakata Y, Yoshizaki A, Nagayasu T, Sekine I (2005) Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors. J Clin Pathol 58: 833–838
Levy DE, Darnell Jr JE (2002) Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3: 651–662
Masuda M, Suzuki M, Yasumatu R, Nakashima T, Kuratomi Y, Azuma K, Tomita K, Komiyama S, Weinstein IB (2002) Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res 62: 3531–3535
Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74–108
Rosen DG, Mercado-Uribe I, Yang G, Bast JR RC, Amin HM, Lai R, Liu J (2006) The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. Cancer 107: 2730–2740
Sakurai K, Satoch T, Takeda N, Hayarama H, Takeda M, Yamamoto R, Fujimoto T, Oikawa M, Fujino T, Fujimoto S (1999) Incidence and distribution pattern of pelvic and paraaortic lymph node metastasis in patients with Stages IB, IIA, and IIIB cervical carcinoma treated with radical hysterectomy. Cancer 85: 1547–1554
Scholz A, Heinez S, Detjen KM, Peters M, Welzel M, Hauff P, Schirner M, Wiedenmann B, Rosewicz S (2003) Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer. Gastroenterology 125: 891–905
Shah NG, Trivedi TI, Tankshali RA, Goswami JA, Jetly DH, Kobawala TP, Shukla SN, Shah PM, Verma RJ (2006) Stat3 expression in oral squamous cell carcinoma: association with clinicopathological parameters and survival. Int J Biol Markers 21: 175–183
Song JI, Grandis JR (2000) STAT signaling in head and neck cancer. Oncogene 19: 2489–2495
Suiqing C, Min Z, Lirong C (2005) Overexpression of phosphorylated-
STAT3 correlated with the invasion and metastasis of cutaneous squamous cell carcinoma. J Dermatol 32: 354–360
Turkson J, Zhang S, Mora LB, Burns A, Sibti S, Jove R (2005) A novel platinum compound inhibits constitutive Stat3 signaling and induces cell cycle arrest and apoptosis of malignant cells. J Biol Chem 280: 32979–32988
Waggoner SE (2003) Cervical cancer. Lancet 361: 2217–2225
Watson CJ, Miller WR (1995) Elevated levels of members of the STAT family of transcription factors in breast carcinoma nuclear extracts. Br J Cancer 71: 840–844
Wegenka UM, Buschmann J, Luticken C, Heinrich PC, Horn F (1993) Acute-phase response factor, a nuclear factor binding to acute-phase response elements, is rapidly activated by interleukin-6 at the posttranslational level. Mol Cell Biol 13: 276–288
Wei LH, Kuo ML, Chen CA, Chou CH, Lai KB, Lee CN, Hsieh CY (2003) Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene 22: 1517–1527
Xi S, Gooding WE, Grandis JR (2005) In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy. Oncogene 24: 970–979
Yang SF, Wang SN, Wu CF, Yeh YT, Chai CY, Chunag SC, Sheen MC, Lee KT (2007) Altered p-STAT3 (tyr705) expression is associated with histological grading and intratumour microvessel density in hepatocellular carcinoma. J Clin Pathol 60: 642–648
Yu CL, Meyer DJ, Campbell GS, Larner AC, Carter-Su C, Schwartz J, Jove R (1995) Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 269: 81–83
Yu H, Jove R (2004) The STATs of cancer – new molecular targets come of age. Nat Rev Cancer 4: 97–105
Zhong Z, Wen Z, Darnell Jr JE (1994) Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264: 95–98
zur Hausen H (2002) Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2: 342–350